Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients

被引：0

作者：

Blanc-Durand, F. ^{[1
]}

Auclin, E. ^{[2
]}

Planchard, D. ^{[1
]}

Ponce Aix, S. ^{[3
]}

Hendriks, L. ^{[4
]}

Sullivan, I. G. ^{[5
]}

Saravia, D. ^{[6
]}

Routy, B. ^{[7
]}

Lopez Castro, R. ^{[8
]}

Pilotto, S. ^{[9
]}

Aboubakar, F. ^{[10
]}

Kassouf, E. ^{[11
]}

Rodriguez, A. ^{[12
]}

Amores Martin, A. ^{[13
]}

Bluthgen, M. V. ^{[14
]}

Duchemann, B. ^{[15
]}

Caramella, C. ^{[16
]}

Nadal, E. ^{[17
]}

Besse, B. ^{[1
]}

Mezquita, L. ^{[1
]}

机构：

[1] Inst Gustave Roussy, Med Oncol, Villejuif, France

[2] Hop European George Pompidou, Gastrointestinal & Med Oncol Dept, Paris, France

[3] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain

[4] Maastricht Univ, Med Ctr, Pulm Dis, Maastricht, Netherlands

[5] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[6] Jackson Mem Hosp, Hematol Oncol Dept, Miami, FL 33136 USA

[7] Univ Montreal, Res Ctr, Hematooncol, Montreal, PQ, Canada

[8] Univ Clin Hosp Valladolid, Med Oncol, Valladolid, Spain

[9] AOU Integrata Borgo Roma Verona, Med Oncol, Verona, Italy

[10] UC Louvain Brussels Woluwe, Dept Oncol Thorac, Brussels, Belgium

[11] Ctr Hosp Reg Lanaudiere, Med Oncol, St Charles Borromee, PQ, Canada

[12] Inst Clin Malalties Hematol & Oncol, Med Oncol, Barcelona, Spain

[13] Hosp Clin Univ Salamanca, Med Oncol, Salamanca, Spain

[14] Hosp Aleman, Med Oncol, Buenos Aires, DF, Argentina

[15] Hop Avicenne, Med Oncol, Bobigny, France

[16] Inst Gustave Roussy, Radiol, Villejuif, France

[17] ICO, Med Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

17P

引用

页码：5 / 5

页数：1

共 50 条

[21] Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials
Varga, A.
Bernard-Tessier, A.
Auclin, E.
Perez, L. Mezquita
Baldini, C.
Planchard, D.
Marabelle, A.
Hollebecque, A.
Besse, B.
Massard, C.
ANNALS OF ONCOLOGY, 2019, 30
[22] Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)
Melia, M. Riudavets
Auclin, E.
Aboubakar, F.
Aix, S. Ponce
Dal Maso, A.
Bluthgen, V.
Mielgo, X.
Mussat, E.
Reyes, R.
Benitez, J.
Lupinacci, L.
Duchemann, B.
de Giglio, A.
Bautista, J.
Audigier-Valette, C.
Scheffler, M.
Campayo, M.
Besse, B.
Planchard, D.
Mezquita, L.
ANNALS OF ONCOLOGY, 2021, 32 : S1384 - S1384
[23] Utility of the Lung Immune Prognostic Index (LIPI) in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab.
Ruiz Banobre, Juan
Areses Manrique, Maria C.
Garcia Campelo, Rosario
Lopez, Rafael
Afonso Afonso, Francisco J.
Casal Rubio, Joaquin
Vazquez Estevez, Sergio
Azpitarte Raposeiras, Cristina
Amenedo, Margarita
Santome, Lucia
Firvida Perez, Jose Luis
Mosquera Martinez, Joaquin
Cortegoso, Alexandra
Vilchez Simo, Rocio
Huidobro Vence, Gerardo
Fernandez Nunez, Natalia
Quiroga Veiga, Nazaret
Garcia Mata, Jesus
Alonso-Jaudenes Curbera, Guillermo
Anido Herranz, Urbano
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[24] Immune Prognostic Index as a predictor of survival in patients with metastatic melanoma treated with immune checkpoint inhibitors
Stukalin, Igor
Suo, Aleksi
Vallerand, Isabelle A.
Lewinson, Ryan
Heng, Daniel Y. C.
Bebb, D. Gwyn
Morris, Don G.
Cheng, Tina
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB100 - AB100
[25] Prognostic Factors of First-Line Immune Checkpoint Inhibitors in Combination with Chemotherapy in Extensive-Stage Small Cell Lung Cancer
Liao, Y. -T.
Sun, R. -L.
Huang, H. -C. H.
Shen, C. -I.
Tseng, Y. -H.
Luo, Y. -H.
Chen, Y. -M.
Chiang, C. -L.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S676 - S676
[26] Baseline IPI (immune prognostic index) predicts survival in patients with advanced cervical cancer treated with immune checkpoint inhibitors (ICI)
Blanc-Durand, F.
Richardson, M.
Vuagnat, P.
Pautier, P.
Hollebecque, A.
Varga, A.
Massard, C.
Leary, A.
ANNALS OF ONCOLOGY, 2019, 30
[27] Association between the modified lung immune predictive index and clinical outcomes of advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors combined with chemotherapy
Xu, Hanyan
Tian, Wenyi
Lin, Xiuxiu
Leong, Tracy L.
Seki, Nobuhiko
Ichiki, Yoshinobu
Su, Shanshan
Chen, Junjie
Li, Yuping
Ye, Junru
JOURNAL OF THORACIC DISEASE, 2023, 15 (11) : 6279 - 6290
[28] Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
Della Gravara, Luigi
Battiloro, Ciro
Cantile, Rosa
Letizia, Antonietta
Vitiello, Fabiana
Montesarchio, Vincenzo
Rocco, Danilo
LUNG CANCER MANAGEMENT, 2020, 9 (01)
[29] Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy
Araki, Taisuke
Tateishi, Kazunari
Komatsu, Masamichi
Sonehara, Kei
Kanda, Shintaro
Hanaoka, Masayuki
Koizumi, Tomonobu
THORACIC CANCER, 2022, 13 (07) : 1006 - 1013
[30] Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Mezquita, Laura
Auclin, Edouard
Ferrara, Roberto
Charrier, Melinda
Remon, Jordi
Planchard, David
Ponce, Santiago
Paz Ares, Luis
Leroy, Laura
Audigier-Valette, Clarisse
Felip, Enriqueta
Zeron-Medina, Jorge
Garrido, Pilar
Brosseau, Solenn
Zalcman, Gerard
Mazieres, Julien
Caramela, Caroline
Lahmar, Jihene
Adam, Julien
Chaput, Nathalie
Soria, Jean Charles
Besse, Benjamin
JAMA ONCOLOGY, 2018, 4 (03) : 351 - 357

← 1 2 3 4 5 →